Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sartorius Stedim Biotech

BATS-CHIXE:DIMP
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DIMP
BATS-CHIXE
€17B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
DIMP Share Price and Events
7 Day Returns
13.4%
BATS-CHIXE:DIMP
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
56%
BATS-CHIXE:DIMP
-15.8%
GB Life Sciences
-23%
GB Market
DIMP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sartorius Stedim Biotech (DIMP) 13.4% 4.5% 22.1% 56% 209% 443.7%
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • DIMP outperformed the Life Sciences industry which returned -15.8% over the past year.
  • DIMP outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
DIMP
Industry
5yr Volatility vs Market

DIMP Value

 Is Sartorius Stedim Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sartorius Stedim Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sartorius Stedim Biotech.

BATS-CHIXE:DIMP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:DIMP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.1%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.033 (1 + (1- 33%) (0.8%))
1.026
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.026 * 6.07%)
6.76%

Discounted Cash Flow Calculation for BATS-CHIXE:DIMP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sartorius Stedim Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:DIMP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.76%)
2020 174.67 Analyst x5 163.61
2021 225.91 Analyst x6 198.22
2022 278.05 Analyst x2 228.53
2023 315.57 Est @ 13.49% 242.95
2024 345.88 Est @ 9.6% 249.43
2025 369.68 Est @ 6.88% 249.73
2026 388.08 Est @ 4.98% 245.56
2027 402.22 Est @ 3.64% 238.40
2028 413.11 Est @ 2.71% 229.36
2029 421.60 Est @ 2.06% 219.26
Present value of next 10 years cash flows €2,265.00
BATS-CHIXE:DIMP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €421.60 × (1 + 0.53%) ÷ (6.76% – 0.53%)
€6,807.14
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €6,807.14 ÷ (1 + 6.76%)10
€3,540.21
BATS-CHIXE:DIMP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,265.00 + €3,540.21
€5,805.21
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €5,805.21 / 92.18
€62.98
BATS-CHIXE:DIMP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:DIMP represents 0.97923x of ENXTPA:DIM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.97923x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 62.98 x 0.97923
€61.67
Value per share (EUR) From above. €61.67
Current discount Discount to share price of €179.20
= -1 x (€179.20 - €61.67) / €61.67
-190.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Sartorius Stedim Biotech is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sartorius Stedim Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sartorius Stedim Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:DIMP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €2.54
ENXTPA:DIM Share Price ** ENXTPA (2020-03-30) in EUR €183
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sartorius Stedim Biotech.

BATS-CHIXE:DIMP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:DIM Share Price ÷ EPS (both in EUR)

= 183 ÷ 2.54

71.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius Stedim Biotech is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • Sartorius Stedim Biotech is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Sartorius Stedim Biotech's expected growth come at a high price?
Raw Data
BATS-CHIXE:DIMP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 71.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
17.6%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:DIMP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 71.91x ÷ 17.6%

4.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius Stedim Biotech is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Sartorius Stedim Biotech's assets?
Raw Data
BATS-CHIXE:DIMP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €12.57
ENXTPA:DIM Share Price * ENXTPA (2020-03-30) in EUR €183
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:DIMP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:DIM Share Price ÷ Book Value per Share (both in EUR)

= 183 ÷ 12.57

14.56x

* Primary Listing of Sartorius Stedim Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius Stedim Biotech is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Sartorius Stedim Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Sartorius Stedim Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DIMP Future Performance

 How is Sartorius Stedim Biotech expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sartorius Stedim Biotech expected to grow at an attractive rate?
  • Sartorius Stedim Biotech's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Sartorius Stedim Biotech's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Sartorius Stedim Biotech's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:DIMP Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:DIMP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 17.6%
BATS-CHIXE:DIMP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 12.1%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:DIMP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:DIMP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 2,754 1
2023-12-31 2,440 1
2022-12-31 2,188 478 407 5
2021-12-31 1,934 407 355 7
2020-12-31 1,708 313 306 7
2020-03-31
BATS-CHIXE:DIMP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 1,441 310 235
2019-09-30 1,393 291 247
2019-06-30 1,336 261 238
2019-03-31 1,274 270 223
2018-12-31 1,212 227 208
2018-09-30 1,172 226 185
2018-06-30 1,121 225 173
2018-03-31 1,093 196 162
2017-12-31 1,081 175 161
2017-09-30 1,073 165 151
2017-06-30 1,089 169 157
2017-03-31 1,075 146 157

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sartorius Stedim Biotech's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
  • Sartorius Stedim Biotech's revenue is expected to grow by 12.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:DIMP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Sartorius Stedim Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:DIMP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 4.43 4.58 4.20 3.00
2021-12-31 3.89 4.06 3.69 6.00
2020-12-31 3.35 3.51 3.19 6.00
2020-03-31
BATS-CHIXE:DIMP Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 2.54
2019-09-30 2.69
2019-06-30 2.58
2019-03-31 2.43
2018-12-31 2.26
2018-09-30 2.01
2018-06-30 1.88
2018-03-31 1.76
2017-12-31 1.75
2017-09-30 1.65
2017-06-30 1.71
2017-03-31 1.70

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Sartorius Stedim Biotech is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Sartorius Stedim Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sartorius Stedim Biotech has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DIMP Past Performance

  How has Sartorius Stedim Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sartorius Stedim Biotech's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sartorius Stedim Biotech's year on year earnings growth rate has been positive over the past 5 years.
  • Sartorius Stedim Biotech's 1-year earnings growth is less than its 5-year average (12.7% vs 20%)
  • Sartorius Stedim Biotech's earnings growth has exceeded the Europe Life Sciences industry average in the past year (12.7% vs 6.3%).
Earnings and Revenue History
Sartorius Stedim Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sartorius Stedim Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:DIMP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,440.57 234.57 317.56 79.22
2019-09-30 1,392.75 247.15 307.86 68.22
2019-06-30 1,335.75 237.95 301.46 65.32
2019-03-31 1,273.95 223.25 293.26 61.22
2018-12-31 1,212.15 208.05 282.86 60.62
2018-09-30 1,172.43 185.29 277.21 59.71
2018-06-30 1,120.83 173.19 263.51 58.71
2018-03-31 1,093.33 162.19 258.81 57.41
2017-12-31 1,081.03 161.09 257.51 53.21
2017-09-30 1,073.01 151.48 251.59 52.74
2017-06-30 1,088.71 156.88 254.59 49.94
2017-03-31 1,074.61 157.08 249.69 48.84
2016-12-31 1,051.61 153.68 243.69 47.54
2016-09-30 1,008.53 145.20 241.96 46.93
2016-06-30 971.13 142.30 233.76 45.63
2016-03-31 925.73 135.70 225.76 43.23
2015-12-31 884.33 118.00 216.76 41.53
2015-09-30 850.12 110.67 206.89 42.86
2015-06-30 781.42 88.84 197.05 34.52
2015-03-31 733.92 75.57 189.49 39.16
2014-12-31 683.52 72.44 183.85 34.12
2014-09-30 646.08 71.18 173.07 38.90
2014-06-30 619.88 66.98 168.37 38.60
2014-03-31 604.38 68.18 164.77 37.70
2013-12-31 588.38 66.28 159.47 36.00
2013-09-30 567.46 63.16 151.33 33.67
2013-06-30 563.96 65.46 154.82 32.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Sartorius Stedim Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Sartorius Stedim Biotech used its assets more efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Sartorius Stedim Biotech's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Sartorius Stedim Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sartorius Stedim Biotech has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DIMP Health

 How is Sartorius Stedim Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sartorius Stedim Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sartorius Stedim Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sartorius Stedim Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sartorius Stedim Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sartorius Stedim Biotech Company Filings, last reported 3 months ago.

BATS-CHIXE:DIMP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,177.63 83.54 35.55
2019-09-30 1,176.50 89.80 45.90
2019-06-30 1,107.10 121.70 36.30
2019-03-31 1,055.70 91.90 41.50
2018-12-31 1,044.87 132.94 40.60
2018-09-30 975.70 177.60 76.80
2018-06-30 924.90 165.60 42.70
2018-03-31 915.40 143.80 70.20
2017-12-31 879.45 142.18 43.85
2017-09-30 837.80 162.10 59.60
2017-06-30 803.50 182.00 50.20
2017-03-31 807.40 156.30 117.00
2016-12-31 763.56 84.05 41.24
2016-09-30 719.10 111.50 45.30
2016-06-30 677.10 128.50 48.60
2016-03-31 669.80 91.60 43.20
2015-12-31 647.22 99.82 37.74
2015-09-30 628.50 114.80 30.40
2015-06-30 589.90 122.20 35.80
2015-03-31 574.50 95.40 33.00
2014-12-31 539.10 87.64 25.33
2014-09-30 519.60 164.60 51.00
2014-06-30 492.50 175.10 50.50
2014-03-31 497.00 184.50 64.50
2013-12-31 481.84 149.67 42.30
2013-09-30 466.20 137.20 20.00
2013-06-30 452.50 168.20 27.50
  • Sartorius Stedim Biotech's level of debt (7.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (16.3% vs 7.1% today).
  • Debt is well covered by operating cash flow (371.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 98.7x coverage).
X
Financial health checks
We assess Sartorius Stedim Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sartorius Stedim Biotech has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DIMP Dividends

 What is Sartorius Stedim Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.37%
Current annual income from Sartorius Stedim Biotech dividends. Estimated to be 0.49% next year.
If you bought €2,000 of Sartorius Stedim Biotech shares you are expected to receive €7 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Sartorius Stedim Biotech's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.69%).
  • Sartorius Stedim Biotech's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.48%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:DIMP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:DIMP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.96 4.00
2021-12-31 0.93 7.00
2020-12-31 0.81 7.00
2020-03-31
BATS-CHIXE:DIMP Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-02-06 0.680 0.398
2019-03-27 0.570 0.425
2018-04-03 0.460 0.483
2017-04-04 0.420 0.659
2016-02-25 0.333 0.553
2015-04-07 0.217 0.463
2014-04-29 0.200 0.824
2013-03-07 0.183 0.955
2012-07-25 0.167 1.341
2012-02-28 0.167 1.777
2011-03-08 0.150 1.971
2010-03-09 0.100 1.702

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius Stedim Biotech is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Sartorius Stedim Biotech is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Sartorius Stedim Biotech's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Sartorius Stedim Biotech's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • No need to calculate the sustainability of Sartorius Stedim Biotech's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Sartorius Stedim Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sartorius Stedim Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sartorius Stedim Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DIMP Management

 What is the CEO of Sartorius Stedim Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joachim Kreuzburg
COMPENSATION €2,735,000
AGE 54
CEO Bio

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengesellschaft (Alternative Name: Sartorius AG) since November 11, 2005 and its Group Chief Executive Officer since May 1, 2003. Dr. rer. pol. Kreuzburg has been a Member of Executive Board at Sartorius Aktiengesellschaft since November 11, 2002 and served as its “Sprecher” (Spokesman) from May 1, 2003 to November 10, 2005. He serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech SA. He served as the Chief Financial Officer of Sartorius Aktiengesellschaft since May 1, 2003. He served as an Executive for Labor Relations at Sartorius Aktiengesellschaft since September 2009. Dr. rer. pol. Kreuzburg served as the Chairman and Chief Executive Officer of Biotechnology Division at Sartorius Aktiengesellschaft since June 2007 and also served as its President of Biotechnology Division. He served as a Vice President of Treasury and Investor Relations at Sartorius Aktiengesellschaft. He serves as a Director of Sartorius Omnimark Instrument Corporation. He serves as Member of the Board of Directors of IntelliCyt Corporation. He served as Member of the Board of Directors of kSep Holdings, Inc. He served as Member of the Board of Directors of ViroCyt, Inc. He served as Member of the Advisory Board (Beirat) of Hameln Group GmbH, Germany. Chairman of the Advisory Board (Beirat) of Otto Bock Holding GmbH & Co. KG, Germany. He serves as Managing Director of Sartorius Lab Holding GmbH; Managing Director of Sartorius Corporate Administration GmbH; Managing Director of Sartorius Weighing Technology GmbH; Managing Director of SWT Treuhand GmbH; Managing Director of SI Weende-Verwaltungs-GmbH Managing Director of SI Grone 1 -Verwaltungs-GmbH. He served as President of VL Finance S.A.S. He served as Member of Advisory Board at Norddeutsche Landesbank Girozentrale. He has been Director of Sartorius Stedim Biotech S.A. since June 29, 2007. He serves as a Member of Supervisory Board at Carl Zeiss AG. He served as a Director of Biotechnology Division at Sartorius Aktiengesellschaft. He was Research associate at the Institute for Solar Energy Research in Hamelin, Germany from 1992 to 1995. He was Research associate at the Faculty of Economics and Management at the University of Hanover, Germany from 1995to 1999. He was the Executive Board: Vice President, Finances and Investor Relations at Sartorius AG, Goettingen, Germany since May 1, 1999. He is Member of the Executive Board of Sartorius AG, Goettingen, Germany Spokesman (Sprecher) of the Executive Board of Sartorius AG, Goettingen, Germany since November 11, 2002 and May 1, 2003 to November 10, 2005 Respectively. He holds a Doctorate in Economics. Dr. rer. pol. Kreuzburg holds a Degree from Mechanical Engineering from the University of Hannover, Germany.

CEO Compensation
  • Joachim's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Joachim's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Joachim Kreuzburg

TITLE
Chairman & CEO
COMPENSATION
€3M
AGE
54

Heiko Imöhl

TITLE
Vice President of Group Financing & Investor Relations

Petra Kirchhoff

TITLE
Head of Corporate Communications & IR
AGE
50

Gerry Mackay

TITLE
Executive Vice President of Marketing
AGE
57
TENURE
3 yrs

Ben Orzelek

TITLE
Head of Investor Relations
Board of Directors Tenure

Average tenure and age of the Sartorius Stedim Biotech board of directors in years:

2.4
Average Tenure
56
Average Age
  • The average tenure for the Sartorius Stedim Biotech board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joachim Kreuzburg

TITLE
Chairman & CEO
COMPENSATION
€3M
AGE
54

Lothar Kappich

TITLE
Non-Executive Director
COMPENSATION
€55K
AGE
62
TENURE
2.4 yrs

Pascale Boissel

TITLE
Independent Non Executive Director
COMPENSATION
€37K
AGE
53
TENURE
1 yrs

Henri Riey

TITLE
Non-Executive Director
COMPENSATION
€46K
AGE
58
TENURE
12.7 yrs

Anne-Marie Graffin

TITLE
Non-Executive Independent Director
COMPENSATION
€46K
AGE
58
TENURE
4.8 yrs

Susan Dexter

TITLE
Non-Executive Independent Director
COMPENSATION
€38K
AGE
64
TENURE
4.8 yrs

René Fáber

TITLE
Non Executive Director
AGE
44
TENURE
1 yrs

Amélie Buton

TITLE
Employee Representative Non Executive Director
AGE
33
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sartorius Stedim Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sartorius Stedim Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DIMP News

Simply Wall St News

DIMP Company Info

Description

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, fluid management services, and membrane chromatography services. In addition, the company offers data analytics software for modeling and optimizing processed of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Details
Name: Sartorius Stedim Biotech S.A.
DIMP
Exchange: BATS-CHIXE
Founded: 1870
€16,868,974,770
92,180,190
Website: http://www.sartorius.com
Address: Sartorius Stedim Biotech S.A.
Zone Industrielle Les Paluds,
Avenue de Jouques – CS 91051,
Aubagne,
Provence-Alpes-Côte d'Azur, 13781,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA DIM Share Capital Euronext Paris FR EUR 01. Jul 2007
OTCPK SDMH.F Share Capital Pink Sheets LLC US USD 01. Jul 2007
DB 56S1 Share Capital Deutsche Boerse AG DE EUR 01. Jul 2007
LSE 0RG8 Share Capital London Stock Exchange GB EUR 01. Jul 2007
BATS-CHIXE DIMP Share Capital BATS 'Chi-X Europe' GB EUR 01. Jul 2007
Number of employees
Current staff
Staff numbers
6,203
Sartorius Stedim Biotech employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 20:25
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/02/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.